Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00222144 · ClinicalTrials.gov registry record · Phase 2
Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by University of Kansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00222144 is a Phase 2 study that has completed, run by University of Kansas. The registered enrollment target is 23 participants.
The verdict
NCT00222144, a Phase 2 study, has completed, sponsored by University of Kansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The primary goal of this study is to determine the effects of the combination of Gleevec and Taxotere in lung cancer in terms of control and reduction of the cancer size. The study will also test lung cancer to see if the presence of certain protein called receptor for platelet derived growth factor can influence the effect of the treatment.
Interventions
- DRUG Gleevec and Taxotere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2004-09 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00222144
The ClinicalTrials.gov registry entry for NCT00222144 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gleevec and Taxotere is the first listed.
NCT00222144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00222144 about?
NCT00222144 is a clinical study titled "Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer". The primary goal of this study is to determine the effects of the combination of Gleevec and Taxotere in lung cancer in terms of control and reduction of the cancer size. The study will also test lung cancer to see if the presence of certain protein called receptor for platelet derived growth factor...
What is the current status of trial NCT00222144?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2004-09. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00222144?
The interventions under investigation include: Gleevec and Taxotere (DRUG).
Who is sponsoring clinical trial NCT00222144?
This trial is sponsored by University of Kansas, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.